FDA approval of a new pediatric indication for BESPONSA®
Pfizer Oncology is proud to announce the FDA approval of a new pediatric indication for BESPONSA® (inotuzumab ozogamicin). The following information is available for review: · Full Prescribing Information Including Boxed Warning